| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Imatinib D4 targets the same kinases as its unlabeled parent drug. Imatinib is an orally bioavailable multi-kinase inhibitor of v-Abl, c-Kit and PDGFR. It is a tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.
|
|---|---|
| ln Vitro |
Imatinib D4 is primarily used as an analytical internal standard rather than for its pharmacological activity. Imatinib is an orally bioavailable multi-kinase inhibitor of v-Abl, c-Kit and PDGFR approved for cancer treatment (e.g. a number of leukemias).
|
| ln Vivo |
Imatinib D4 is used in pharmacokinetic studies as an internal standard for the quantification of Imatinib. Imatinib is an orally bioavailable tyrosine kinase inhibitor approved for cancer treatment. The deuterium-labeled compound can be co-administered with unlabeled drug to study absorption, distribution, metabolism, and excretion.
|
| Enzyme Assay |
In vitro enzyme assays for Imatinib D4 are typically performed as part of analytical method validation. The compound is used as an internal standard in LC-MS/MS assays for the quantification of Imatinib. It is dissolved in an appropriate solvent and spiked into biological matrices at known concentrations. Calibration curves are generated by plotting the peak area ratio of Imatinib to Imatinib D4 against the concentration of Imatinib.
|
| Cell Assay |
For in vitro cell-based assays, Imatinib D4 can be used in studies investigating Imatinib's cellular effects, though its primary use is as an analytical internal standard. Cancer cell lines are cultured and treated with the compound. Kinase inhibition is confirmed by measuring the phosphorylation of downstream signaling proteins via Western blot. Cell viability is assessed by MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies with Imatinib D4 are primarily pharmacokinetic. The compound is administered orally to rodents, and blood samples are collected at predetermined time points. Plasma concentrations of both labeled and unlabeled Imatinib are analyzed by LC-MS/MS using Imatinib D4 as the internal standard. Pharmacodynamic effects can be evaluated in xenograft models.
|
| ADME/Pharmacokinetics |
Imatinib D4 (CAS: 1134803-16-9) has a molecular weight of 497.63 g/mol and a molecular formula of C₂₉H₂₇D₄N₇O. Appearance: Off-white to light yellow solid powder. Storage: Powder -20°C. The compound is a tetra-deuterated form of Imatinib.
|
| Toxicity/Toxicokinetics |
As a deuterium-labeled analog of an approved drug, Imatinib D4 is expected to have a similar toxicity profile to Imatinib, though toxicity studies are typically not performed on the labeled compound. Imatinib is generally well-tolerated, with common side effects including edema and gastrointestinal disturbances. The compound is used in very small quantities as an analytical internal standard.
|
| References |
|
| Additional Infomation |
Imatinib D4 is a tetra-deuterated form of Imatinib (STI571; Gleevec or Glivec), an orally bioavailable multi-kinase inhibitor of v-Abl, c-Kit and PDGFR approved for cancer treatment. It is used as an internal standard for analytical method development and pharmacokinetic studies. It is not intended for therapeutic use and is for research and analytical use only.
|
| Molecular Formula |
C29H27D4N7O
|
|---|---|
| Molecular Weight |
497.63
|
| Exact Mass |
497.284
|
| CAS # |
1134803-16-9
|
| Related CAS # |
Imatinib;152459-95-5
|
| PubChem CID |
25235771
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
706
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C=C(C)C(NC2=NC=CC(C3=CN=CC=C3)=N2)=CC=1NC(=O)C1=C([2H])C([2H])=C(CN2CCN(C)CC2)C([2H])=C1[2H]
|
| InChi Key |
KTUFNOKKBVMGRW-YKVCKAMESA-N
|
| InChi Code |
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)/i6D,7D,8D,9D
|
| Chemical Name |
2,3,5,6-tetradeuterio-4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0095 mL | 10.0476 mL | 20.0953 mL | |
| 5 mM | 0.4019 mL | 2.0095 mL | 4.0191 mL | |
| 10 mM | 0.2010 mL | 1.0048 mL | 2.0095 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
